These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 33866578)

  • 1. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA; Pinner NA; Lisenby KM; Osmonson A
    Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F
    Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609
    [No Abstract]   [Full Text] [Related]  

  • 10. Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes.
    Vlasschaert C; Sidhu B; Silver SA
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):361-368. PubMed ID: 33767064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA; Pinner NA
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ; Butler J; Kosiborod MN
    Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
    Blair HA
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):701-710. PubMed ID: 34651263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
    Rodriguez R; Kaluzna SD
    Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
    Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
    Jhalani NB
    Adv Ther; 2022 Aug; 39(8):3472-3487. PubMed ID: 35699903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.